These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 11808833)

  • 1. Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital.
    Mitra S; Findley K; Frohnapple D; Mehta JL
    Clin Cardiol; 2002 Jan; 25(1):16-8. PubMed ID: 11808833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the care of patients with acute myocardial infarction at a university-affiliated Veterans Affairs Medical Center.
    Bansal D; Gaddam V; Aude YW; Bissett J; Fahdi I; Garza L; Joseph J; Molavi B; Pai BV; Sinha A; Smith ES; Mehta JL
    J Cardiovasc Pharmacol Ther; 2005 Mar; 10(1):39-44. PubMed ID: 15821837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
    Barron HV; Michaels AD; Maynard C; Every NR
    J Am Coll Cardiol; 1998 Aug; 32(2):360-7. PubMed ID: 9708461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction.
    Kizer JR; Cannon CP; McCabe CH; Mueller HS; Schweiger MJ; Davis VG; Perritt R; Antman EM
    Am Heart J; 1999 Jan; 137(1):79-92. PubMed ID: 9878939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of patients who have suffered an acute myocardial infarction in a tertiary care centre.
    Haddad H; Searles G; Gillis A
    Can J Cardiol; 2001 Feb; 17(2):179-83. PubMed ID: 11223488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence.
    Simpson E; Beck C; Richard H; Eisenberg MJ; Pilote L
    Am Heart J; 2003 Mar; 145(3):438-44. PubMed ID: 12660666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the management of acute myocardial infarction in Southern Tasmania.
    McNamara KS; Peterson GM; Friesen WT
    J Clin Pharm Ther; 2000 Apr; 25(2):111-8. PubMed ID: 10849188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic therapies after myocardial infarction.
    Rapaport E; Gheorghiade M
    Am J Med; 1996 Oct; 101(4A):4A61S-69S; discussion 4A69S-70S. PubMed ID: 8900339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
    Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction.
    Gutstein DE; Fuster V
    Clin Cardiol; 1998 Mar; 21(3):161-8. PubMed ID: 9541759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients.
    Zuanetti G; Latini R
    J Diabetes Complications; 1997; 11(2):131-6. PubMed ID: 9101399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
    Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease.
    Sanal S; Aronow WS
    J Gerontol A Biol Sci Med Sci; 2003 Nov; 58(11):1046-8. PubMed ID: 14630888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention?
    McCormick D; Gurwitz JH; Lessard D; Yarzebski J; Gore JM; Goldberg RJ
    Arch Intern Med; 1999 Mar; 159(6):561-7. PubMed ID: 10090112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profile of survivors of acute myocardial infarction at Turkish academic hospitals.
    Ergin A; Abaci A; Sakalli A; Eryol NK; Oguzhan A; Unal S; Cetin S
    Int J Cardiol; 1999 Mar; 68(3):309-16. PubMed ID: 10213283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction.
    Majumdar SR; Inui TS; Gurwitz JH; Gillman MW; McLaughlin TJ; Soumerai SB
    J Gen Intern Med; 2001 Jun; 16(6):351-9. PubMed ID: 11422631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
    Berger AK; Duval S; Krumholz HM
    J Am Coll Cardiol; 2003 Jul; 42(2):201-8. PubMed ID: 12875751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis.
    van der Elst ME; Bouvy ML; de Blaey CJ; de Boer A
    Clin Ther; 2005 Nov; 27(11):1806-14. PubMed ID: 16368451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is prophylactic treatment after myocardial infarction evidence-based?
    Brotons C; Calvo F; Cascant P; Ribera A; Moral I; Permanyer-Miralda G
    Fam Pract; 1998 Oct; 15(5):457-61. PubMed ID: 9848433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.